The overall goal ofthe comparative animal core is to support the development and use ofthe animal models employed within this Program Project Grant. The guiding principals for the comparative animal core are efficient planning and utilization of tissue and tumor samples, standardization of processing and diagnoses, and continued development of the canine spontaneous tumor animal model. This Core is housed and coordinated in the Department of Veterinary Biosciences in the College of Veterinary Medicine at OSU and includes individuals with expertise in comparative pathology, tissue banking, and clinical trial development and execution. Dr. Cheryl London, the proposed Core Director, is a Board Certified Veterinary Medical Oncologist with extensive expertise in cancer drug development including validating novel targets, identifying appropriate small molecules for target inhibition, and testing these compounds in relevant canine cancers with the goal of providing critical information that can assist in the human drug development process. Drs. Krista La Perie and Brad Bolon, Co-Investigators, are Board Certified in Veterinary Anatomic Pathology and are experts in the field of comparative pathology, particularly with respect to mouse models of cancer and evaluation of novel therapeutics in these models. The primary objective of this Core is to assist investigators in determining both the toxicities and activity associated with novel therapeutic approaches in mouse models of sarcoma, to identify candidate drugs/treatments that are likely to have success in the clinical setting, and to evaluate these treatments in dogs with spontaneous sarcomas as a prelude to future human clinical trials. As such, the specific aims of this Core are to: 1) Provide a standardized histopathologic evaluation of sarcomas generated in mouse models of disease following treatment with various targeted therapeutics;2) Identify adverse effects associated with treatment of mice with novel therapeutics. 3) Provide high quality normal and tumor tissue samples from dogs with spontaneous sarcomas;and 4) Assess the adverse event profile and biologic activity of a novel STATS inhibitor (LY5) in normal dogs and dogs with spontaneous osteosarcoma.

Public Health Relevance

The proposed Core is relevant as it assists in the integration of drug development efforts in mice with those in dogs and provides a platform to help rapidly move findings generated in vitro and mouse sarcoma models into the clinical setting. Given the challenges with respect to clinical trials in pediatric patients, the proposed Core will facilitate identifying therapeutic strategies most likely to be successful in this patient population.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Nationwide Children's Hospital
United States
Zip Code
Cam, Maren; Gardner, Heather L; Roberts, Ryan D et al. (2016) ΔNp63 mediates cellular survival and metastasis in canine osteosarcoma. Oncotarget :
Bid, Hemant K; Phelps, Doris A; Xaio, Linlin et al. (2016) The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther 15:1018-28
Murphy, Brendan; Yin, Han; Maris, John M et al. (2016) Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Res 76:5798-5809
Wu, Xiaojuan; Xiao, Hui; Wang, Ruoning et al. (2016) Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells. Curr Cancer Drug Targets 16:631-8
Forest, Amelie; Amatulli, Michael; Ludwig, Dale L et al. (2015) Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor. Mol Cancer Res 13:1615-26
Studebaker, Adam; Bondra, Kathryn; Seum, Star et al. (2015) Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. Pediatr Blood Cancer 62:1768-74
Phelps, Doris; Bondra, Kathryn; Seum, Star et al. (2015) Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. Pediatr Blood Cancer 62:1345-52
Adamson, Peter C; Houghton, Peter J; Perilongo, Giorgio et al. (2014) Drug discovery in paediatric oncology: roadblocks to progress. Nat Rev Clin Oncol 11:732-9
Singh, Mamata; Leasure, Justin M; Chronowski, Christopher et al. (2014) FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene. Clin Cancer Res 20:3884-95
Bid, Hemant K; Roberts, Ryan D; Cam, Maren et al. (2014) ýýNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis. Cancer Res 74:320-9

Showing the most recent 10 out of 14 publications